Amyotrophic Lateral Sclerosis (ALS)

High-Calorie Diet May Help in ALS

A study supported in part by MDA has found that a high-calorie, high-carbohydrate diet is safe and well-tolerated in late-stage amyotrophic lateral sclerosis (ALS), that it leads to moderate weight gain, and that it may slow disease progression.

New ALS Mouse Model Has Human FUS Mutation

Augie’s Quest To Transition from MDA to the ALS Therapy Development Institute

Clump-Busting Molecule Targets Misfolded Proteins in ALS

ALS Care Checklist Developed

International ALS Symposium Stresses Progress

"We are undoubtedly slowing down the MND [motor neuron disease] supertanker, and can start to see how we might turn it around for the first tim," said Martin Turner, senior clinician scientist at the University of Oxford (United Kingdom), on research being reported on at the 24th International Symposium on ALS/MND.

Immune System Modulator in Development for ALS

ALS Nuedexta Study Seeks 60 Participants

The Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) is actively seeking people with amyotrophic lateral sclerosis (ALS) to participate in a phase 2 clinical trial designed to evaluate whether Nuedexta has any effects on bulbar functions including speech, swallowing and saliva function.

Antisense Against C9ORF72 ALS and FTD

Results from three recent studies — two supported in part by MDA — shed light on how the chromosome 9 open reading frame 72 (C9ORF72) mutation causes nerve cell death in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Multicenter Trial to Test Immunosuppression in ALS

Trial investigators are actively seeking people with amyotrophic lateral sclerosis (ALS) to participate in a phase 2 clinical trial that will evaluate the effects of a five-drug treatment regimen used to suppress immune system activity.

Pages